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Background: Opportunistic recruitment is a highly laborious and time-consuming process that is currently performed
manually, increasing the workload of already busy practitioners and resulting in many studies failing to achieve their
recruitment targets. The Translational Medicine and Patient Safety in Europe (TRANSFoRm) platform enables automated
recruitment, data collection and follow-up of patients, potentially improving the efficiency, time and costs of clinical
research. This study aims to assess the effectiveness of TRANSFoRm in improving patient recruitment and follow-up in
primary care trials.
Methods/design: This multi-centre, parallel-arm cluster randomised controlled trial will compare TRANSFoRm-supported
with standard opportunistic recruitment. Participants will be general practitioners and patients with gastro-oesophageal
reflux disease from 40 primary care centres in five European countries. Randomisation will take place at the care centre
level. The intervention arm will use the TRANSFoRm tools for recruitment, baseline data collection and follow-up. The
control arm will use web-based case report forms and paper self-completed questionnaires. The primary outcome will be
the proportion of eligible patients successfully recruited at the end of the 16-week recruitment period. Secondary
outcomes will include the proportion of recruited patients with complete baseline and follow-up data and the proportion
of participants withdrawn or lost to follow-up. The study will also include an economic evaluation and measures of
technology acceptance and user experience.
Discussion: The study should shed light on the use of eHealth to improve the effectiveness of recruitment and follow-up
in primary care research and provide an evidence base for future eHealth-supported recruitment initiatives. Reporting of
results is expected in October 2015.
Trial registration: EudraCT: 2014-001314-25Introduction
Background
Recruitment to primary care trials is a particularly challen-
ging process with most studies struggling to reach their
recruitment targets. In fact, a survey of authors of 39 pub-
lished primary care trials found that only 29% of UK pri-
mary care studies achieved their recruitment targets* Correspondence: n.mastellos@imperial.ac.uk
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unless otherwise stated.within the agreed timeframe, with 70% requiring add-
itional time to recruit the predefined number of partici-
pants [1]. This is very worrying considering that clinical
trials succeed or fail based on whether they manage to re-
cruit the sufficient number of participants to enable re-
searchers to generate accurate results to precisely and
reliably answer the question at hand. Recruitment failings
can result in studies lacking statistical power to produce
significant results, increasing the risk that an effective
health intervention will be abandoned before its real im-
pact has been demonstrated [2]. Consequently, improvingal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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portant for the future of medical research.
Evidence suggests that the most effective method of re-
cruitment in primary care is opportunistic recruitment [3].
This involves approaching eligible primary care patients
when they visit their general practitioner (GP) and inviting
them to take part. Opportunistic recruitment takes place in
a highly stressful and time-pressured clinical environment
and relies on busy GPs directly inviting patients within the
consultation [4]. As a result, this method can be very chal-
lenging and slow with practitioners often failing to translate
the initial enthusiasm into recruitment targets [5].
The increased adoption of electronic health records
(EHR) systems in primary care provides the opportunity for
real-time identification of eligible participants through the
use of clinical trial alert systems [6-9]. Such systems notify
GPs about eligible patients during the consultation allowing
them to immediately discuss the trial with the patient to
enable instant recruitment, thus negating the need for
laborious effort on the part of the practitioner, patient or
researcher [10]. The Translational Medicine and Patient
Safety in Europe (TRANSFoRm) project team has devel-
oped a suite of software tools and underlying infrastructure
to support patient recruitment to primary care studies
across multiple sites and countries, potentially saving time
for busy practitioners and patients in the consultation room
[11]. This protocol describes a cluster randomised con-
trolled trial evaluating the effectiveness of the TRANSFoRm
system in improving patient recruitment and follow-up in
primary care trials.
The TRANSFoRm system supports secure, provenance-
enabled design, deployment and collection of patient-
reported outcome measures (PROM) and electronic case
report forms (eCRF) through web and mobile applications
as well as EHR systems in the primary care centres where
the trials are taking place, as shown in Figure 1. The GP-
facing tools enable automated identification, eligibility
check, randomisation, baseline and follow-up data collec-
tion and reporting of data in clinical studies, while theFigure 1 TRANSFoRm system components.patient-facing tools support collection of patient-reported
data through mobile or web applications.
Figure 2 shows the TRANSFoRm-supported clinical trial
workflow, starting with a patient visiting their GP for their
consultation. Potential participants are identified using a
clinical trial alert tool that notifies the GP that the patient
fulfils specific inclusion criteria, after checking for diagno-
ses, symptoms and/or treatment prescriptions. Once iden-
tified, the GP can check for the first set of inclusion and
exclusion criteria and, if the patient is still suitable, collect
informed consent for further screening. Next, clinical data
from the patient’s electronic record is extracted to popu-
late fields in the eCRF. The system alerts the practitioner
about any missing data and presents the study dataset for
final approval. PROM data is incorporated into the eCRF
via a web or mobile application used by participants to
record symptoms, signs and other self-reported outcomes.
The system randomises enrolled patients and reports allo-
cation instantly so that the study intervention can be initi-
ated without delay. Participants are then followed up
using the mobile or web applications and the eCRF tool at
GP visits. Following GP approval, the study dataset is de-
livered to the researcher through a secure data transport
mechanism that communicates with TRANSFoRm con-
nector tools on the participating EHR.
The development of the clinical study workflow has
been structured around a clinical study which acts as a
use case for the evaluation of TRANSFoRm. The gastro-
oesophageal reflux disease (GORD) study employs a ran-
domised controlled trial design to answer the following
question: “What gives most symptom relief and improve-
ment in quality of life in patients with GORD, on de-
mand or continuous use of proton pump inhibitors?”.
Participants will be patients with GORD, aged 18–65
years old. The study will take place in five countries and
will involve 16-week recruitment and 8-week follow-up.
The follow-up time was chosen because proton pump
inhibitor (PPI) treatment is known to have an effect after
2 weeks. Therefore, 8 weeks should be sufficient to
Figure 2 TRANSFoRm clinical trial workflow.
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role of TRANSFoRm in this study is to identify preva-
lent and incident cases of GORD, randomise patients to
on-demand or continuous use of PPI and follow up
these patients using mobile or web applications and
eCRF completed by GPs at primary care visits. Further
details about the clinical study will be provided in a sep-
arate publication.
Aim and objectives
The study described in this protocol aims to assess the
effectiveness of TRANSFoRm in patient recruitment
compared to standard GP-led opportunistic recruitment.
The study hypothesis is that TRANSFoRm will increase
patient recruitment by 15%, from 20% to 35%, compared
to standard practice.
The objectives of the study are:
1. To evaluate the effectiveness of TRANSFoRm in
recruiting patients to clinical trials.
2. To assess its effectiveness in collecting complete
baseline and follow-up data.
3. To compare the costs of recruitment in the
TRANSFoRm and control arms.
4. To explore practitioner and patient experience and
acceptability of the system.
Methods/design
Trial design
We plan to conduct a 24-week, multi-centre, parallel-arm
cluster randomised controlled trial of TRANSFoRm recruit-
ment compared to GP-led opportunistic recruitment. The
intervention arm will use the TRANSFoRm tools for partici-
pant recruitment, baseline data collection and follow-up.
The control arm will rely on standard GP-led recruitment
using web-based CRFs for baseline data collection and
paper-based questionnaires for follow-up. The study willrun in five countries (United Kingdom, The Netherlands,
Belgium, Poland, and Greece) with eight primary care cen-
tres in each country, giving a total of 40 centres. Of these,
20 will be randomised to the TRANSFoRm arm and 20 to
control on a 1:1 allocation ratio. Potentially eligible partici-
pants will be identified and recruited using TRANSFoRm or
standard GP recruitment, with the hypothesis being that
TRANSFoRm will yield 35% recruitment rate compared to
20% for the standard method. Participants will be finally
randomised to on-demand or continuous use of PPI as part
of the clinical protocol for the GORD study (Figure 3).
Participants
The intervention will be implemented at the primary
care centre level. To be eligible for participation, primary
care centres should use an EHR system compatible with
TRANSFoRm, provide written agreement to participate
in the GORD study, agree to participate in whichever
arm they are randomly allocated, have a list size of over
2,000 patients and be able to identify at least 100 eligible
participants over the 16-week recruitment period. Pri-
mary care centres lacking an appropriate EHR system or
centres that have migrated from paper-based record
keeping within the last 12 months will be excluded. Pri-
mary care centre characteristics, such as list size and
GORD prevalence, will be gathered from GP database
audit to inform recruitment. Local project partners will
liaise with the study coordinator to recruit care centres
that meet the above criteria.
Study participants will be GPs located in primary care
centres receiving the TRANSFoRm intervention or standard
recruitment method, and GORD patients using the web/
mobile- or paper-based method for recording self-reported
data. To be eligible for participation, patients should be
GORD cases with heartburn and/or acid regurgitation that
need PPI treatment, aged 60–85. Pregnant women, patients
with a myocardial infraction within 6 months of the study
Figure 3 Study design—a two-arm cluster randomised controlled trial comparing TRANSFoRm with standard GP-led opportunistic
recruitment.
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excluded from the study.
Informed consent will be sought from all sites. Primary
care centres will provide informed consent as a unit.
This may vary from all GPs signing the consent form to
one GP being authorised to sign on behalf of the centre.
Patients will consent in accordance with the require-
ments of the GORD trial. The participating centres will
receive €17 compensation for each correctly enrolled pa-
tient. Patients will not receive any incentive for taking
part. Participants are not expected to experience any
harm as a result of their participation in the evaluation
study, as their involvement is restricted to completing
the PROM questionnaires. Despite including health in-
formation, it is unlikely that these questionnaires will ad-
dress any sensitive issues.
Setting
We aim to recruit 40 urban, suburban and rural primary
care centres in and around five European sites: London
(United Kingdom), Utrecht (The Netherlands), Antwerp
(Belgium), Wroclaw (Poland) and Heraklion-Crete (Greece).
A dedicated member of the study team will liaise with local
coordinators in each country to recruit eligible practices.
Detailed practice characteristics will be provided in future
publications.
Intervention and control
Primary care centres allocated to the intervention arm will
use the TRANSFoRm tools for participant recruitment,
baseline data collection and follow-up. When visiting their
GP, potentially eligible patients will be flagged by the sys-
tem so that their GP can check for the first set of inclusionand exclusion criteria and, if appropriate, collect informed
consent for further screening. Next, clinician-reported
outcome measures (CROM) data from the patient’s health
record will populate fields into the patient’s eCRF. The
system will notify the GP about any missing data. Upon
GP approval, the system will randomise patients to on-
demand or continuous use of PPI. Participants will then
receive information on how to fill out the PROM fields on
their smartphone or the web. When participants return
for the follow-up visit after 8 weeks, as stipulated in the
clinical protocol, the CROM data is activated; the GP
checks all prefilled fields and adds any missing data. If the
participant does not attend the second visit, the GP will
receive a reminder. PROM data is provided by the partici-
pants within 3 days from the second visit using the mo-
bile/web application. Participants will receive reminders 2,
3 and 4 days after the visit, if the self-reported data is not
provided.
Control centres will use standard GP-led opportunistic
recruitment and data collection methods. Patients will
be identified as potentially eligible by their GP after
checking their health record during the consultation.
The GP will check for the exclusion criteria, and, if the
patient is still eligible, they will provide them with infor-
mation about the study. Upon patient consent, the GP
will complete the CROM fields and the patient will be
randomised to on-demand or continuous use of PPI fol-
lowing the randomisation design for the GORD study
(i.e. block randomisation containing four blocks based
on age and gender). The patient will receive a question-
naire to complete either at the primary care centre or at
home. Patients will be followed up using paper-based
questionnaires.
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The primary outcome measure is the proportion of eligible
patients successfully recruited using the TRANSFoRm
method compared to standard GP-led opportunistic recruit-
ment. A record of all identified, screened and successfully
recruited patients will be kept using data from GP systems.
The percentage of those recruited in the trial will be com-
pared to identify whether TRANSFoRm yields a higher
number of recruited patients compared to standard GP
recruitment.
Secondary outcomes
Secondary outcomes will include the proportion of
GORD cases recruited with complete baseline and
follow-up data, as well as the proportion of those giving
informed consent to participate but later withdrawing
from the study. All electronic or paper-based CRFs
completed by the recruited patients in each group will
be reviewed, and retention data will be collected to
examine whether there is a difference in the percentage
of patients with complete data and the numbers of par-
ticipants withdrawn or lost to follow up among the two
arms.
Economic evaluation
A cost analysis will estimate the costs of recruitment using
the TRANSFoRm system and the standard method. A
similar approach was adopted in a previous study compar-
ing recruitment methods across sites [12]. The analysis
will focus on the direct costs incurred to the primary care
centre during the implementation and operation phases.
Patient and third party costs will not be included. Trial ad-
ministration costs, including labour and material costs
and personnel time spent will be identified and combined
with recruitment data to model the average cost per site
and enrolled participant. Non-recurring costs will spread
out over 15 years and will be discounted at a 3.5% rate. If
TRANSFoRm results in increased recruitment but is also
more costly, the cost per additional participant will be es-
timated to assess whether this excess cost is acceptable.
Technology acceptance survey
User acceptance of the TRANSFoRm tools will be mea-
sured in a centrally coordinated technology acceptance
survey. The Technology Acceptance Model (TAM) ques-
tionnaire is a validated instrument for collecting post hoc
perceptions of a technology artefact segregated into two
domains: usefulness and ease of use [13-15]. Data will be
collected retrospectively through an electronically distrib-
uted questionnaire to all intervention arm participants.
User experience interviews
Clinician and patient experience with the TRANSFoRm
tools will be assessed in follow-up, semi-structured, in-depth interviews with a purposive sample of interesting
cases (i.e. GPs and patients with positive and negative ex-
periences who demonstrated high/low usage patterns dur-
ing the study). This interview study aims to assist
interpretation of quantitative data generated by the main
evaluation study by exploring: i) methods of recruitment
and follow-up (e.g. web/mobile- vs. paper-based PROM);
ii) reasons for any observed variations in recruitment per-
formance across sites; iii) barriers and facilitators to suc-
cessful recruitment; and iv) areas for improvements.
Sample size
We estimated the average number of eligible GORD pa-
tients per primary care centre to be at least 100 during
the 16-week recruitment phase, based on a conservative
GORD prevalence of 10% [16] and a list size of 2,000
patients. We conducted a binominal power calculation
taking into account the variation in centre characteris-
tics. This showed that 536 participants across 40 cen-
tres, 20 per arm, will give the study 90% power to detect
a 15% increase in recruitment, from 20% to 35%, using a
conservative 5% intra-cluster correlation coefficient, at
5% significance level. Modelling conducted for the clin-
ical study suggests that this will offer excess power to
detect a clinically relevant change in self-rated health
scores (±0.25 Reflux Disease Questionnaire points) be-
tween treatment groups.
Randomisation, allocation and blinding
Primary care centres will be assigned to the TRANSFoRm
or control arm on a 1:1 allocation ratio. The allocation se-
quence will be computer-generated using a within-
country permuted random block design with blocks of
two matched for list size, GORD prevalence, location, ra-
tio of GORD appointments per week to list size and ratio
of GPs to list size. The study is unblinded as it is impos-
sible to blind primary care centres or investigators to the
intervention. However, the allocation will not be shared
with those involved in the data analysis to maintain ob-
jectivity and minimise bias.
Statistical methods
The percentage of patients recruited to the study for the
intervention and control groups will be calculated using de-
scriptive statistics with 95% confidence intervals. These will
be presented separately for each site, country and overall.
The proportion of eligible participants recruited will be
compared between groups using logistic regression, ad-
justed for clustering by centre by using generalised estimat-
ing equations (CI 95%, P < .05). Between-group differences
in recruitment rate will be analysed using chi-square tests.
This method will be also applied to compare the percentage
of participants with complete data and the percentage of
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lost to follow up.
Descriptive statistics will be used to outline the relative
proportion of participants who were satisfied or dissatisfied
with the TRANSFoRm tools as per item on the TAM ques-
tionnaire. Quantitative data will be analysed in STATA (v13)
using an intention-to-treat approach.
Data from the user experience interviews will be
audio-recorded, transcribed verbatim and analysed the-
matically using Ritchie and Spencer’s framework ana-
lysis approach [17].
The study has been designed and will be reported in
CONSORT-compliant format [18].
Handling and storage of data
The study will be conducted according to good clinical
practice standards. The handling of personal data will com-
ply with the Personal Data Protection Act 2012 and local
data protection regulations. Data collected from EHR sys-
tems and mobile/web applications using the TRANSFoRm
system will be stored in a secure site hosted by Custodix (a
private company specialising in data protection solutions in
eHealth). TRANSFoRm has implemented technical mea-
sures to ensure that identifiable personal data is protected
and that study data in the TRANSFoRm study system is
protected by access authorisation and pseudonyms. Data
for the control group will be transcribed from the paper-
based forms via a web-based clinical data capture system
hosted on a secure data repository at King’s College
London. At the end of the study, all data will be securely
transferred to Custodix to create the analysis dataset. This
will only contain pseudonymised data. After analysis and
reporting, data will be archived at the Karolinska Institutet
in Stockholm for 15 years.
Discussion
Recruitment failures in primary care are common due to
the complexity of recruiting patients in this setting. To date,
the most effective method for recruiting patients to primary
care trials is opportunistic recruitment. This is performed
manually using paper- or web-based case report forms and
relies on busy GPs actively approaching potentially eligible
patients in the consultation room and inviting them to take
part. In an increasingly demanding healthcare system, such
methods are highly time-consuming, and as a result, many
studies fail to achieve their recruitment targets or to even
recruit a single patient [1,19,20]. Recent advancements in
information technology have enabled researchers, technolo-
gists and clinicians to collaborate with the aim to develop
systems that can overcome these challenges and support ef-
fective recruitment. The TRANSFoRm system aims to
transform patient recruitment and follow-up in primary
care by automating the processes for identifying, recruiting
and following up patients, potentially saving time for healthprofessionals, which can be used instead in care delivery.
The study described in this protocol will evaluate the effect-
iveness of TRANSFoRm in improving the efficiency, time
and costs of recruitment and data collection. The study will
provide an evidence base for eHealth-supported recruit-
ment and follow-up in primary care. Participant recruit-
ment is scheduled to commence in February 2015 and be
completed by May 2015. The scheduled end of follow-up
data collection is July 2015. Reporting of results is expected
in October 2015.
The study design has been tailored to the objectives of
the evaluation and the characteristics of the GORD study.
The evaluation focuses on the socioeconomic aspects of
the system. The main goal is to ensure that TRANSFoRm
can improve the efficiency, time and costs of conducting
clinical research in primary care. The evaluation strategy
draws on valid and reliable methods which have been
widely used in health informatics research to assess the ef-
fectiveness of eHealth interventions [21]. The study will
use quantitative and qualitative data collection techniques
that enable triangulation of findings adding to the internal
validity of the study. It will recruit urban, suburban and
rural primary care centres in five countries and will em-
ploy culturally diverse study participants increasing the
sample representativeness and thus external validity.
The evaluation will include patients with GORD, and
otherwise eligible for the study, for whom a single clinic ap-
pointment was made during the recruitment period. This
measure guards against the possibility that participating
centres embark on an active programme of recruitment of
potential participants rather than, as instructed, relying on
opportunistic presentation. Local EHR and appointment
datasets will be used to validate this process. An in-depth
audit will be undertaken of any centre where the appoint-
ment rate lies more than two standard deviations from the
within-country mean. In all other centres, a random selec-
tion of appointments created for GORD patients during the
recruitment period will be audited by an evaluation team
member in liaison with a local collaborator.
The study has some weaknesses. The scope of the eco-
nomic analysis is limited to the care centre level. This
practically means that we cannot assess the costs and
benefits for all stakeholders in the project. However, pa-
tients will be able to provide qualitative feedback on the
impact of the TRANSFoRm tools in follow-up inter-
views and a TAM survey. Another limitation is that the
study timeline is relatively short to evaluate the long-
term effects of the intervention, despite being sufficient
to recruit the required number of participants and col-
lect data to explore the evaluation aims. Considering
that technology adoption is a complex process [22,23],
the time from implementation to evaluation is relatively
short to assess the performance of the TRANSFoRm
system.
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ducting a summative evaluation of the TRANSFoRm sys-
tem based on the GORD clinical trial. The evaluation study
focuses on assessing the effectiveness of TRANSFoRm-
supported recruitment and follow-up in primary care
research compared with standard GP-led opportunistic re-
cruitment. The study should provide useful information
about the use of information technology to improve the ef-
ficiency, time and costs of recruitment and follow-up in pri-
mary care and is expected to provide an evidence base for
future eHealth-supported recruitment initiatives.
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